Addition of 20mg/Day Zeaxanthin to Triple Therapy Treatment Options for Age Related Macular Degen… (NCT01527435) | Clinical Trial Compass
CompletedNot Applicable
Addition of 20mg/Day Zeaxanthin to Triple Therapy Treatment Options for Age Related Macular Degeneration (ARMD)
United States200 participantsStarted 2011-12
Plain-language summary
The purpose of this study is to evaluate the fact that 20 milligrams per day of oral Zeaxanthin as a supplement to patients with Choroidal neovascularization (CNV) and exudative age related macular degeneration (ARMD) undergoing combination therapy with intravitreal Bevacizumab (Avastin), intravitreal Dexamethasone and PDT laser photocoagulation and improves anatomic and visual outcome compared to patients not receiving oral Zeaxanthin. Study patients will be taking AREDS(PreserVision) and multivitamins (Centrum Silver); in addition one-half of the patients will receive 20mg of oral Zeaxanthin.
Who can participate
Age range50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male or female at least 50 years of age.
✓. Subjects must have age related macular degeneration with a choroidal neovascular membrane either classic or occult in at least one eye.
✓. Preoperative best corrected visual acuity (BCVA) equal to or greater to 19 letters on the ETDRS diabetic retinopathy study chart (20/400 Snellen).
✓. Media clarity, pupillary dilation and subject cooperation sufficient for accurate OCT and angiographic assessment.
✓. Written and informed consent has been obtained.
✓. Written authorization for the use and release of the health and research study information in the United States of America USA.
✓. Ability to understand the informed consent and willingness to follow study instruction and likely to complete all required visits and procedures.
Exclusion criteria
✕. Evidence of diabetic retinopathy or other retinal disease other than age related macular degeneration.
What they're measuring
1
BEST CORRECTED VISUAL ACUITY AFTER TREATMENTS
Timeframe: 3, 6 12, 15, 18 AND 24 MONTHS AFTER ENTRY
. Any severe active ocular disease or condition that in the opinion of the investigator is severe enough to prevent a 3 line improvement in visual acuity or to compromise the study results.
✕. Any presumed ocular infections, i.e. bacterial, viral, parasitic, or fungal in either eye at the baseline visit.
✕. Contraindication to pupillary dilation in either eye.
✕. Uncontrolled systemic disease.
✕. Any condition (including inability to read visual acuity charts and language barriers) which precludes subjects ability to comply with the study requirements including the completion of the study.
✕. Subject has a condition or is in a situation which the investigator's opinion may put the subject at significant risk, may confound the study results or may interfere significantly with the subjects participation in the study.